Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14 USD | -1.86% | +1.58% | -35.12% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.12% | 911M | |
+28.81% | 49.46B | |
+0.40% | 42.58B | |
+49.22% | 42.49B | |
-5.26% | 29.09B | |
+12.24% | 26.61B | |
-24.24% | 18.64B | |
+7.35% | 13.16B | |
+32.01% | 12.55B | |
+24.12% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Viridian Therapeutics Appoints Carrie Melvin to Fill New COO Role